Alternative lengthening of telomeres in primary hepatic neoplasms

被引:4
|
作者
Yasir, Saba [1 ]
Thompson, Scott [2 ]
Chen, Zongming Eric [1 ]
Knudson, Ryan [3 ]
Knutson, Darlene [3 ]
Kloft-Nelson, Sara [3 ]
Graham, Rondell P. [1 ]
Jain, Dhanpat [4 ]
Simon, Sanford M. [5 ]
Wu, Tsung-Teh [1 ]
Torbenson, Michael [1 ]
机构
[1] Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Radiol, Rochester, MN 55905 USA
[3] Mayo Clin, Cytogenet Core Lab, Med Genome Facil, Rochester, MN 55905 USA
[4] Dept Pathol, Yale, CT 06520 USA
[5] Rockefeller Univ, Lab Cellular Biophys, 1230 York Ave, New York, NY 10065 USA
关键词
Hepatocellular carci-noma; Fibrolamellar carcinoma; Angiosarcoma; Cholangiocarcinoma; Alternative lenthening of telomeres; Combined hepatocellular carcinoma-cholangio-carcinoma; Carcinosarcoma; CANCER; TUMORS; ATRX; CARCINOMA; PHENOTYPE; DAXX;
D O I
10.1016/j.humpath.2022.11.003
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The alternative lengthening of telomeres (ALT) phenotype is characterized by ultra-bright telomeres on fluorescence in situ hybridization (FISH) and is a marker of a unique mechanism of telo-mere maintenance in tumors. ALT does not occur in normal tissues. ALT has been described in hepa-tocellular carcinoma (5-10%) and in primary hepatic angiosarcomas (75%). To study the frequency of ALT in other primary hepatic tumors, a wide range of primary hepatic neoplasms were retrieved. The tumors included the following: intrahepatic and hilar cholangiocarcinomas (N = 110), hepatic ade-nomas (N = 35), hepatocellular carcinomas (N = 30), fibrolamellar carcinomas (n = 11), combined cholangiocarcinoma-hepatocellular carcinomas (N = 8), carcinosarcoma (N = 10), hepatoblastomas (N = 5), hemangiomas (N = 4), angiosarcomas (N = 8), epithelioid hemangioendotheliomas (N = 10), calcified nested stromal epithelial tumor (N = 2), embryonal sarcoma (N = 2), rhabdoid tumor (N = 1), bile duct adenoma (N = 1), and angiomyolipoma (N = 1). For epithelial tumors, ALT-FISH was positive in one carcinosarcoma (10% of cases), one cholangiocarcinoma (1% of cases), and one combined hepatocellular carcinoma-cholangiocarcinoma (13% of cases). In the hepatocellular carcinoma component of both the carcinosarcoma and the combined hepatocellular carcinoma-cholangiocarcinoma, the tumor cells showed patchy marked nuclear pleomorphism akin to that described previously for chromophobe hepatocellular carcinoma, which are typically ALT FISH pos-itive. The ALT-positive cholangiocarcinoma also showed patchy, striking nuclear pleomorphism. For soft tissue tumors, ALT was positive in two angiosarcomas (N = 2; 25% of cases). In summary, this study shows that ALT-FISH is positive in rare carcinosarcomas, cholangiocarcinomas, and combined cholangiocarcinoma-hepatocellular carcinoma. ALT is not a significant mechanism of telomere main-tenance in hepatocellular adenomas or fibrolamellar carcinomas and was negative in all other tested primary hepatic neoplasms. ALT-FISH is also positive in a subset of primary hepatic angiosarcomas.(c) 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:79 / 86
页数:8
相关论文
共 50 条
  • [1] A Comprehensive Survey of Primary Hepatic Neoplasms for the Altered Lengthening of Telomeres Phenotype
    Graham, Rondell
    Jain, Dhanpat
    Torbenson, Michael
    LABORATORY INVESTIGATION, 2018, 98 : 635 - 635
  • [2] A Comprehensive Survey of Primary Hepatic Neoplasms for the Altered Lengthening of Telomeres Phenotype
    Graham, Rondell
    Jain, Dhanpat
    Torbenson, Michael
    MODERN PATHOLOGY, 2018, 31 : 635 - 635
  • [3] Mechanisms of Alternative Lengthening of Telomeres
    O'Sullivan, Roderick J.
    Greenberg, Roger A.
    COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2025, 17 (01):
  • [4] A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas
    Henson, JD
    Hannay, JA
    McCarthy, SW
    Royds, JA
    Yeager, TR
    Robinson, RA
    Wharton, SB
    Jellinek, DA
    Arbuckle, SM
    Yoo, JY
    Robinson, BG
    Learoyd, DL
    Stalley, PD
    Bonar, SF
    Yu, DH
    Pollock, RE
    Reddel, RR
    CLINICAL CANCER RESEARCH, 2005, 11 (01) : 217 - 225
  • [5] Alternative lengthening of telomeres in human cells
    Reddel, RR
    Bryan, TM
    Colgin, LM
    Perrem, KT
    Yeager, TR
    RADIATION RESEARCH, 2001, 155 (01) : 194 - 200
  • [6] Alternative Lengthening of Telomeres and Chromatin Status
    Udroiu, Ion
    Sgura, Antonella
    GENES, 2020, 11 (01)
  • [7] Alternative lengthening of telomeres, telomerase, and cancer
    Reddel, RR
    CANCER LETTERS, 2003, 194 (02) : 155 - 162
  • [8] Alternative lengthening of telomeres in mammalian cells
    Henson, JD
    Neumann, AA
    Yeager, TR
    Reddel, RR
    ONCOGENE, 2002, 21 (04) : 598 - 610
  • [9] Alternative lengthening of telomeres in human cancer
    Reddel, Roger
    Cesare, Anthony
    Jiang, Wei-Qin
    Pickett, Hilda
    CANCER RESEARCH, 2009, 69
  • [10] Alternative lengthening of telomeres in mammalian cells
    Jeremy D Henson
    Axel A Neumann
    Thomas R Yeager
    Roger R Reddel
    Oncogene, 2002, 21 : 598 - 610